Greenwich LifeSciences to build out internal clinical trial operations team

Greenwich LifeSciences (GLSI) announced its plan to build out its internal clinical trial management and operations team. The company has begun to hire its own staff to manage and operate its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, while reducing its dependence on more expensive staffing from Clinical Research Organizations. The strategy to bring in key clinical functions inside the company is expected to reduce costs over the remaining duration of the clinical trial and to increase efficiency and quality as the clinical trial continues to increase the number of enrolling sites and the number of approved participating countries. As this buildout continues, and as the burn rate is simultaneously reduced, the Company believes it will have more options to respond to the needs of FLAMINGO-01 or to add additional pipeline indications or product lines.